Sandoz Ups Biosimilar Game With Alteogen Subcutaneous Tech Deal

Alteogen Comments Suggests Deal Worth Up To $145m

Sandoz is eyeing development of up to three subcutaneous formulation biosimilars, which offer greater benefits to both patients and healthcare providers, via a technology agreement with Korean firm Alteogen.

Alliance
Alteogen is also developing a biosimilar eylea product • Source: Shutterstock

Sandoz has acquired worldwide rights to Korean player Alteogen’s novel human recombinant human hyaluronidase enzyme (ALT-B4) to develop and commercialize a subcutaneous version of one of its own biosimilar products.

Meanwhile, the Novartis affiliate’s agreement includes an option for Sandoz to license ALT-B4, which is derived using the company’s Hybrozyme...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.